Company Highlights - Voyager Therapeutics is focused on delivering the next generation of gene therapies[1] - The company is extending its cash runway into early 2023[5] Technology Platform - Voyager Therapeutics utilizes proprietary AAV capsids to power second-generation efforts in Huntington's disease and ALS, and pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations[5] - The company is increasing platform investment to expand discovery of novel targeted AAV capsids and clinical application of vectorized antibodies[5] - TRACER AAV capsids offer superior transduction of targeted tissues enabling lower dose GTx using IV delivery to target CNS, cardiac, and skeletal muscle[7] - The company's vectorized mAb platform aims to achieve therapeutic antibody levels to CNS via IV delivery to overcome very low CNS penetration of traditional mAbs, with preclinical POC demonstrated with an anti-tau program and exploration into neuro-oncology indication[7] - Voyager Therapeutics is advancing best-in-class GTxs leveraging superior TRACER capsids across CNS indications, potentially allowing for IV administration, lower dosing, favorable safety, and superior CNS tissue distribution[7] - Multiple candidates show a 10-1000-fold improvement in CNS & spinal cord transduction compared to AAV9[10]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-3003182 ( ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-300318 ...

Call Start: 16:30 January 1, 0000 5:07 PM ET Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2020 Earnings Conference Call February 25, 2021 16:30 ET Company Participants Allison Dorval - Chief Financial Officer Andre Turenne - President & Chief Executive Officer Omar Khwaja - Chief Medical Officer & Head of R&D Conference Call Participants Phil Nadeau - Cowen Ken Shields - Wedbush Hannah Latimer - Morgan Stanley Aydin Huseynov - Benchmark Operator Good afternoon, and welcome to the Voyager Therapeutics Fourth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-3003182 (State o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) (State or other juris ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ______ to ______ Securities registered pursuant to Section 12(b) of the Act: Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name o ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2019 Earnings Conference Call March 3, 2020 4:30 PM ET Company Participants Paul Cox - Head of Investor Relations Andre Turenne - President & Chief Executive Officer Omar Khwaja - Chief Medical Officer & Head of R&D Allison Dorval - Chief Financial Officer Conference Call Participants Laura Chico - Wedbush Charles Duncan - Cantor Fitzgerald Aaron Welch - H. C. Wainwright Hannah Latimer - Morgan Stanley Yanan Zhu - Wells Fargo Silvan Tuerkcan - Oppenheimer Operator ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-3003182 (State o ...